CNSP News and Press, CNS Pharmaceuticals Inc. From 12/28/22

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers CNS’s flagship drug candidate is called Berubicin, a product ...

Scientists at the University of Pennsylvania School of Medicine and Intel Corp. carried out a large-scale international machine learning effort to collect knowledge from brain scans of more than 6,000 patients with glioblastoma at various sites globally. Their objective was to develop a model t...

CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system The company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain ba...

New research has found that cooling brain tumors improves rates of survival, which offers hope for new options for treatment for patients suffering from difficult brain cancers. The most common type of brain cancer, glioblastoma multiforme, is a fast-growing and aggressive cancer that usually o...

Malignant brain tumors are fast growing and are known to spread to other areas of the brain and spine. These brain tumors are often graded based on how fast they grow and their likelihood of growing back following treatment. The most common type of malignant brain tumor are gliomas, which mak...

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of i...

CNS Pharma ( NASDAQ: CNSP ) announced preliminary results from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM). The results reflected recruitment of a balanced patient population to compare Berubicin to Lomustine in the treatment...

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM) PR Newswire Data recently presented at the Society for Neuro-Oncology (SNO) 27 th Annual Meeting ...

According to Cancer.org, slightly more than 10,000 children under the age of 15 will be diagnosed with pediatric cancer by the end of the year. While more than 80% of children with cancer in high-income countries such as the United States are treated successfully, data shows that these cancer t...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor ...